Vascular endothelial growth factor (
VEGF) contributes to airway
inflammation and angiogenesis in
asthma.
Hypoxia inducible factor (HIF), the most potent regulator of
VEGF, is a heterodimer of a constitutively expressed beta subunit and an
oxygen-regulated alpha subunit (HIF-alpha). Three HIF-alpha
isoforms have been described, of which
HIF-2 alpha are abundantly expressed in lung tissue.
Neovastat is a naturally occurring inhibitor of angiogenesis derived from marine cartilage. We previously reported that
Neovastat can inhibit the airway
inflammation in
asthma. In this study, we hypothesized that the anti-inflammatory effect of
Neovastat is mediated with inhibition of
VEGF and
HIF-2 alpha. BALB/c mice were immunized subcutaneously and challenged with inhaled
ovalbumin (OVA).
Neovastat was administrated by gavage three times with 12-h interval, beginning at 30 min before OVA inhalation.
VEGF concentration in bronchoalveolar lavage fluid was measured by ELISA. We evaluate the expression of
VEGF and
HIF-2 alpha in lung tissue by immunohistochemistry. Mice treated with
Neovastat had significantly reduced inflammatory cell count in BAL fluid compared with untreated asthmatic mice. Furthermore, Mice treated with
Neovastat showed significantly reduced
VEGF and
HIF-2 alpha expression on lung tissue. These results suggest that anti-inflammatory effects of
Neovastat could be linked to inhibition of
VEGF and
HIF-2 alpha.